Genome Therapeutics Changes Name to Oscient Pharmaceuticals Corporation to Reflect Focus on Drug Development and Commercializati
"As we prepare for the launch of FACTIVE(R) tablets, we believe it is important for our new company name to more accurately reflect our mission and strategy," stated Steven M. Rauscher, President and CEO of Oscient Pharmaceuticals. "The name Oscient Pharmaceuticals, with its strong root in pharmaceutical science, reflects our continued commitment to the commercialization and clinical development of our pipeline."
At the Company's Annual Meeting held today in Boston, shareholders approved all five proposals presented for vote. Oscient's corporate headquarters will remain in Waltham, Massachusetts, with west coast offices in South San Francisco.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.